BioTrinity Establishes Itself as the Leading Biopartnering and Investment Conference in Europe

LONDON, May 15, 2014 /PRNewswire/ --

BioTrinity's  move  to  London  a  record  success:  attendance  breaks  the  1,000  mark  

OBN - the membership organisation supporting the UK's emerging life sciences companies - announces today that BioTrinity, its annual conference, has achieved record attendance, with 1,000 delegates present, building on its position as the leading biopartnering and investment conference in Europe.  

Jon Rees, CEO of OBN, said: "The success of our first BioTrinity in London has surpassed our expectations. We have attracted a record number of delegates from the UK and internationally, with a very strong attendance from investors and pharma partners. In addition to our compelling panel sessions, we saw the announcement of new initiatives aimed at improving the funding environment for emerging life sciences companies, and new data pointing to a strong fundraising year in Europe. Following the new corporate identity for OBN and the year-on-year growth of BioTrinity, we believe we are in an even stronger position to serve our members."  

The success of BioTrinity 2014 as the premier European biopartnering conference is reflected by another year of consecutive growth:

• 1,000 delegates from over 625 companies from 34 countries across Europe, Asia and North America;
• Participation of more than 130 delegates from 100 investment firms from 13 countries specialising in funding emerging biotechnology and life science companies as well as more than 80 pharmaceutical company delegates;
• 113 company pitches for partners and investment (up 30%) among 185 speakers throughout the two-day conference
• This year saw more than 2,500 one-to-one partnering meetings scheduled, continuing the growth trend from 1,700 meetings in 2013 (up 50%)
• Growing demand for and participation in 8 specialised workshops
• Medtech-focused MediTrinity Track for the first time at BioTrinity

Graziano Seghezzi, Partner at Sofinnova Partners led a panel discussing trends and differences between the US and Europe in life sciences venture capital. He comments, "The outcome of the very high level debate was that the buoyant public markets now offer venture capital investors in the life sciences a historical opportunity to start building companies again. 

"There's been a step change in the quality and size of BioTrinity, which the OBN team are building into one of the premier biopartnering conferences in Europe."

About  OBN

OBN is the membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our Membership of over 300 companies, spread across the Golden Triangle (formed by the cities of Oxford, Cambridge and London) and beyond to Nottingham, Manchester and Scotland, benefits from tailored networking and partnering events, group purchasing, advice, consultancy and advocacy.  

OBN founded and produces BioTrinity, Europe's largest annual Biopartnering and Investment Conference for emerging companies. Attracting around 1,000 senior delegates from Europe, Asia and North America, BioTrinity generates more R&D-company-to-investor interactions than any similar European event.  

For further information on OBN and its activities, visit: http://www.obn.org.uk. To find out more about BioTrinity, visit http://www.biotrinity.com. 

Contacts
OBN
Jon Rees, CEO
Tel: +44 (0)845-5049-722 or +44 (0)7795-233883
Email: [email protected]

Citigate  Dewe  Rogerson
Sita Shah/Janine Hagan
Tel: +44(0)207-638-9571
Email:  [email protected] /[email protected]

SOURCE OBN